FDA Law Blog: Biosimilars

FEBRUARY 9, 2024

Overall, the final guidance provides many editorial clarifications as well as some noteworthy updates, including discussions on DHTs that meet the definition of a device, selection of a DHT and rationale for use in a clinical investigation, retention and protection of data collected by DHTs, and DHT updates.

FDA 105

FDA Compliance Regulations Engineering 105

FDA Law Blog: Biosimilars

JULY 11, 2023

To set the stage for this case, we need to go back to March 2020 , when a new definition of “biological product” threw the world of protein products into a tizzy. As a result of the Biologics Price Competition and Innovation Act (BPCIA) passed in 2010, the definition of a “biological product” expanded to include “proteins.”

FDA 95

FDA Regulations Production Small Molecule 95

FDA Law Blog: Biosimilars

APRIL 25, 2023

510(k), premarket approval application (PMA), Product Development Protocol (PDP), De Novo, or Humanitarian Device Exemption (HDE)] for a device that meets the definition of a cyber device under this section shall include such information as [FDA] may require to ensure that such cyber device meets the cybersecurity requirements. . . .

FDA 105

FDA Regulations Production Drugs 105

FDA Law Blog: Drug Discovery

FEBRUARY 2, 2023

The definition goes on to list potential options for such tests: cell-based assays, organ chips and microphysiological systems, computer modeling, other nonhuman or human biology-based test methods such as bioprinting, as well as animal tests. For more on FDORA’s other provisions, see HPM’s complete summary here ). FDORA § 3209(a)(2).

Animal Testing 64

Animal Testing Biosimilars Cell Based Assays FDA 64

FDA Law Blog: Biosimilars

JUNE 13, 2024

Though the Court acknowledged that the definition of the term “drug” is broad enough to include the ProAir HFA inhaler, the Court found that “this broad statutory definition of drug does not suffice to establish the Inhaler Patents claim the drug for which Teva submitted its application.”

FDA 116

FDA FDA Approval Production Drugs 116

FDA Law Blog: Biosimilars

MAY 6, 2024

FDA interprets the “software” definition to include software that is firmware or programmable logic in addition to software in a medical device (SiMD) or software as a medical device (SaMD). For medical devices that meet the definition of a cyber device, manufacturers are required to submit specific information in premarket submissions.

FDA 105

FDA Regulations Marketing Drugs 105

FDA Law Blog: Biosimilars

JULY 23, 2024

Drug delivery includes successful product preparation and the initiation, progression, and completion of dose delivery.

FDA 105

FDA Drugs Pharmacokinetics Production 105

Drug Channels

FEBRUARY 21, 2023

Pharmacies and Pharmacy Benefit Managers is a definitive, nonpartisan resource that includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and much more. The 2023 Economic Report on U.S.

Pharmacy 97

Pharmacy Specialty Pharmacies Licensing Licensing 97

FDA Law Blog: Biosimilars

FEBRUARY 21, 2024

Both ISO 13485 and ISO 9000 contain terms and definitions that are referenced within Part 820. FDA further retained some definitions in the QSMR. FDA further retained some definitions in the QSMR. Certain definitions are also removed from § 820.3, Revised § 820.3

FDA 59

FDA Regulations Packaging Compliance 59

FDA Law Blog: Biosimilars

AUGUST 4, 2023

DASCA amended the CSA by revising and adding specified substances to the definition of “anabolic steroid,” providing for the temporary and permanent scheduling of anabolic steroids and adding labeling requirements for products containing anabolic steroids. Implementation of the Designer Anabolic Steroid Control Act of 2014 , 88 Fed.

Regulations 52

Regulations Production Drugs Clinical Trials 52

Drug Channels

SEPTEMBER 12, 2023

2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors Economic Report on Pharmaceutical Wholesalers and Specialty Distributors is the definitive, nonpartisan resource thoroughly updates our annual exploration of the distribution industry’s interactions with—and services for—other participants in our healthcare system.

Pharmaceuticals 40

Pharmaceuticals Pharmacy Biosimilars Licensing 40

FDA Law Blog: Biosimilars

SEPTEMBER 18, 2024

By Riëtte van Laack — The dietary supplement exclusionary clause is, as its name suggests, a clause in the Federal Food, Drug, and Cosmetic Act (FDC Act) definition of dietary supplement. On August 28 of this year, NPA sued FDA challenging FDA’s determination that NMN is excluded from the dietary supplement definition.

Production 59

Production FDA Licensing Licensing 59

FDA Law Blog: Biosimilars

SEPTEMBER 25, 2024

From Chapter 1 (My First Generic Drug Client), through Chapter 4 (The Hatch-Waxman Act), to Chapter 12 (My Prescription for the Future), the 208-page “Breaking the Medicine Monopolies: Reflections of a Generic Drug Pioneer” is definitely worth a read!

Drugs 59

Drugs Pharmaceuticals 59

FDA Law Blog: Biosimilars

APRIL 10, 2023

Houck — Drugs and substances classified within schedule I of the federal Controlled Substances Act (“CSA”) by definition have a high potential for abuse, no currently accepted medical use in treatment in the United States, and lack accepted safety for use under medical supervision. By Larry K. 21 U.S.C. § 802(a) (7)(A)).

Research 59

Research Therapies Clinical Trials Treatment 59

FDA Law Blog: Biosimilars

OCTOBER 9, 2023

As applied to manufacturer assistance, CMS did not adopt a single interpretation of the statutory or regulatory definition of “cost sharing.” The Court specifically concluded that the rule “rests on two contradictory interpretations of the statute” and “conflict[s] with the regulatory definition.”

Pharmacy 40

Pharmacy Regulations Drugs 40

FDA Law Blog: Biosimilars

AUGUST 14, 2024

Among other topics, the memorandum summarizes CMS’s proposed regulations for both these Part B and Part D inflation rebate programs, including: Key definitions; The drugs to which the rebates apply; Methods of calculating and applying rebates; Processes for reporting, reconciling, and paying rebates; and Penalties and enforcement.

Regulations 59

Regulations Drugs Pharmaceuticals 59

FDA Law Blog: Biosimilars

MAY 15, 2023

A major component of AAFCO is its work on ingredient definitions, specifying what ingredients may be use in animal feed under what conditions. AAFCO’s ingredient definitions are not federal regulations and do not have the force or effect of federal law. The goal is to create uniformity to facilitate interstate commerce.

Regulations 45

Regulations FDA Approval FDA Production 45

Agency IQ

JUNE 9, 2023

Other orphan drugs, which, by definition, address an unmet medical need, “only” receive 9 years of market exclusivity. Reduced market exclusivity would foster generic and biosimilar competition through earlier market access. Generic and biosimilar developers benefit from earlier market entry.

Marketing 40

Marketing Regulations Biosimilars Drugs 40

FDA Law Blog: Biosimilars

JUNE 12, 2023

Moreover, ingredients used in pet food must be approved by FDA, affirmed or listed as Generally Recognized as Safe (GRAS) by FDA, or go through the AAFCO definition process. PFI’s president has stated that “[t]he biggest issue is the inconsistency in state interpretation of AAFCO label definitions.

Regulations 45

Regulations FDA Production Government 45

Agency IQ

SEPTEMBER 22, 2023

As captured in the definition of the PDURS itself, the software must be “disseminated by or on behalf of a drug sponsor.” This definition is carried forward in the new PDURS framework: “A software function [per the Cures Act] is any distinct purpose of the software—in this case, prescription drug use-related software.

FDA 40

FDA Biosimilars Production Drugs 40

FDA Law Blog: Biosimilars

MARCH 5, 2024

If enacted, the legislation would amend the FMIA and PPIA to establish definitions for “imitation” and “cell-cultured” meat and poultry products, and revise the definitions of “meat” and “poultry” to exclude such products. This particular federal legislative effort, however, continues the debate.

Protein Production 59

Protein Production Production DNA Regulations 59

FDA Law Blog: Biosimilars

FEBRUARY 13, 2025

FDA provides definitions for the three datasets. Update practices and training of end users also need to be addressed. Data management practices should include how the manufacturer plans to obtain and use training, tuning, and test data to support each AI-DSF modification.

FDA 71

FDA Marketing Regulations Production 71

FDA Law Blog: Biosimilars

MARCH 5, 2024

Even if the company did obtain approval, such approval would likely be after generic competition for Farxiga enters the market, in which case the definition of a qualifying single source drug would no longer apply to Farxiga. AstraZeneca argued it would very likely have products in future lists of drugs selected for negotiations.

Government 64

Government Marketing Production Drugs 64

FDA Law Blog: Biosimilars

JUNE 28, 2023

The proposed legislation appears to be an effort to resolve issues created by FDA’s Center for Veterinary Medicine’s (CVM) interpretation of the Federal Food, Drug, and Cosmetic Act (FDC Act) definition of food.

Regulations 45

Regulations Production Drugs Disease 45

FDA Law Blog: Biosimilars

OCTOBER 6, 2023

Change to the IVD definition First, the mechanics of the change. The crux of the proposed rule lies in the addition of ten words: “ including when the manufacturer of these products is a laboratory.” These words would be added to the definition of “ in vitro diagnostic [IVD] products” in 21 C.F.R.

Laboratories 64

Laboratories FDA Regulations Production 64

FDA Law Blog: Biosimilars

FEBRUARY 6, 2024

In fairness, we’d note that FDA reports that inspections are on the rise—but definitely not back to pre-pandemic levels. The Subcommittee majority has held prior hearings and written letters about these problems, as the issue has vexed FDA in recent years.

Testimonials 52

Testimonials FDA International Laboratories 52

FDA Law Blog: Biosimilars

MARCH 16, 2023

Thus, ironically the definition of “simple” is anything but and is almost certain to lead to debates about what, exactly, is simple. The design and procedures of the device are appropriate for use by healthcare professionals in near-patient settings outside a centralized laboratory.

Marketing 40

Marketing Regulations Laboratories FDA 40

FDA Law Blog: Biosimilars

MARCH 7, 2024

FDA uses that definition to designate small businesses eligible for a reduced user fee. Sections 738(d)(2)(A) and (e)(2)(A) of the FD&C Act define a “small business” as an entity that reported $100 million or less of gross receipts or sales in its most recent income tax return.

FDA 64

FDA Regulations Drugs 64

FDA Law Blog: Biosimilars

OCTOBER 18, 2023

The Draft Guidance also describes the types of data that may constitute clinical data supporting a 510(k), drawing on previous recommendations of the International Medical Device Regulators Forum (see “ Clinical Evidence – Key Definitions and Concepts ”). electronic health records, claims).

FDA 64

FDA Regulations Clinical Trials Marketing 64

FDA Law Blog: Biosimilars

JUNE 17, 2024

Medical gas manufacturers and 503B outsourcing facilities—both of which meet the definition of “manufacturer”—are excluded from the Quality Report. drugs subject to an open drug efficacy study implementation ( DESI ) program proceeding).

Pharmaceuticals 59

Pharmaceuticals FDA Production Drugs 59

FDA Law Blog: Biosimilars

NOVEMBER 1, 2023

The PR goes on to state that the FD&C Act definition of a device does not turn on where or by whom a test system is “manufactured.” FDA recognizes that the FD&C Act exempts licensed healthcare practitioners from certain device regulations if they manufacture devices solely for use in the course of their professional practice.

Laboratories 81

Laboratories FDA Regulations Licensing 81

The Pharma Data

AUGUST 1, 2021

Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $674 Million; Global Rinvoq Net Revenues Were $378 Million – Second-Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $1.816 Billion, an Increase of 14.1 percent on an operational basis, due to biosimilar competition.

FDA 52

FDA Treatment Trials Biosimilars 52

FDA Law Blog: Biosimilars

MAY 10, 2023

802(54)(G) (which references CMS’s statutory definition of “practice of telemedicine”). This time around, DEA is acting jointly with SAMHSA, which agency “concurs” with the temporary rule, and has advised DEA that no additional rulemaking is necessary at this time other than the temporary rule, nor are amendments required to 21 U.S.C. §

Compliance 52

Compliance Regulations Treatment Drugs 52

FDA Law Blog: Biosimilars

JULY 8, 2024

The Court acknowledged that the determination as to whether it concerns a public or private right has not been “definitively explained” but stressed that the public right is an exception and should be interpreted narrowly. The dissent agreed that the critical question is whether the matter concerns a private or public right.

Government 59

Government Trials FDA Clinical Trials 59

FDA Law Blog: Biosimilars

SEPTEMBER 22, 2024

We are not reproducing the questions that were simple recitations of regulatory definitions or FDA’s arguments in the Final Rule. Previously Submitted Questions FDA then proceeded to answer questions that were submitted to the agency before the webinar.

FDA 64

FDA Laboratories Regulations Compliance 64

The Pharma Data

NOVEMBER 9, 2020

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. J Intern Med 2012;272:121–32. 7 Wenzel S. Severe Asthma in Adults. Am J Respir Crit Care Med. 2005; 172; 149–60. 8 Chung KF, Wenzel SE, Brozek JL, et al. Eur Respir J 2014; 43: 343–73. 9 Price D, Fletcher M, van der Molen T.

Trials 52

Trials Production Clinical Trials Government 52

FDA Law Blog: Biosimilars

MAY 19, 2023

Unlike like the definition of “simple test,” the Special Controls are anything but simple. As we stated previously, this submission took well over nine (9) months to review and develop the Special Controls. After reviewing the Special Controls, we understand what took so long.

FDA 40

FDA Marketing Compliance Production 40